Company intelligence / Profile preview
Huaxia Shengsheng Pharmaceutical
Beijing, Beijing Shi, Chinacnverify.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Huaxia Shengsheng Pharmaceutical has a pipeline of at least four small molecule drug programs targeting nervous system diseases, neoplasms, and metabolic disorders. Its lead asset is in Phase 1 for amyotrophic lateral sclerosis; other programs are preclinical. The company has conducted at least 14 clinical trials as of March 2025.
- Therapeutic areas
- NeurologyOncologyEndocrinology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Request access →03
Partnerships
None publicly reported as of June 2025.
Beyond the preview
Go deeper on Huaxia Shengsheng Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Huaxia Shengsheng Pharmaceutical.